Nymox Pharmaceutical new updated Safety Committee review of safety data for its ongoing multi-center U.S. Phase 2 trial of NX-1207 has revealed no serious drug side effects. The entire cohort of enrolled subjects have now all completed their drug dosing in the trial. NX-1207 is Nymox's lead drug candidate for the treatment of benign
prostatic hyperplasia (BPH).
StreetInsider.com
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Senators Question Digital Health Pre-Cert Program
The agency “should be focused on ensuring it has the tools and capacity to guarantee that software products that perform medical device functions are safe and effective and to hold companies that skirt the rules accountable,” the letter states.
Pfizer Gets FDA Nod for Breast Cancer Drug
The agency based its approval on the results of a 431-patient trial.
FDAnews Drug Daily Bulletin
NYMOX PHARMACEUTICAL SAYS SAFETY COMMITTEE REVIEW ON PHASE 2 TRIAL OF NX-1207 REVEALS NO SERIOUS SIDE EFFECTS
June 28, 2006